Differential Effects of p27 in Regulation of β-Cell Mass During Development, Neonatal Period, and Adult Life
- Latif Rachdi1,
- Norman Balcazar1,
- Lynda Elghazi1,
- Daniel J. Barker1,
- Irina Krits1,
- Hiroaki Kiyokawa2 and
- Ernesto Bernal-Mizrachi1
- 1Division of Endocrinology, Metabolism and Lipid Research, Washington University School of Medicine, St. Louis, Missouri
- 2Department of Molecular Pharmacology and Biological Chemistry, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
- Address correspondence and reprint requests to Ernesto Bernal-Mizrachi, Washington University School of Medicine, 660 S. Euclid Ave., Campus Box 8127, St. Louis, MO 63110. E-mail: ebernal{at}wustl.edu
Abstract
β-Cell cycle progression and proliferation are critical to maintain β-cell mass in adult mice. Of the cell cycle inhibitors, p27Kip1 is thought to be the primary modulator of the proliferative status in most cell types. p27 plays a role in β-cell adaptation in genetic models of insulin resistance. To study the role of p27 in β-cells during physiological conditions and at different stages of β-cell differentiation, we studied mice deficient of or overexpressing p27. Experiments in p27-deficient mice showed improved glucose tolerance and hyperinsulinemia. These changes were associated with increased islet mass and proliferation. The experiments overexpressing p27 in β-cells were performed using a doxycycline-inducible model. Interestingly, overexpression of p27 for 16 weeks in β-cells from adult mice had no effect on glucose tolerance, β-cell mass, or proliferation. In contrast, induction of p27 expression during β-cell development or early neonatal period resulted in severe glucose intolerance and reduced β-cell mass by decreased proliferation. These changes were reversible upon discontinuation of doxycycline. These experiments suggest that p27 is a critical molecule for β-cell proliferation during β-cell development and early postnatal life but not for maintenance of adult mass.
- BrdU, bromodeoxyuridine
- cdk, cyclin-dependent kinase
- CKI, cell cycle inhibitor
- INK4, inhibitor of kinase 4
Footnotes
-
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
-
- Accepted September 11, 2006.
- Received June 23, 2006.
- DIABETES














